Evidence map›Paper›PMID 42232607›Full record

ArticleOncology research2026

Clinical Value of the Systemic Immune Inflammation Index and PD-L1 Expression in Advanced NSCLC Treated with Pembrolizumab: Real-World Preliminary Study.

Hyungkeun Cha, Yong Seok Lee, Gui Young Kwon, Boran Kim, Yeonsook Moon, Lucia Kim, Hae-Seong Nam

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hyungkeun ChaDivision of Pulmonology, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, Republic of Korea.
Yong Seok LeeDepartment of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Gui Young KwonPathology Division, Seoul Clinical Laboratories, Yongin-si, Gyeonggi-do, Republic of Korea.
Boran KimIncheon-Namdong Branch, National Health Insurance Corp., Incheon, Republic of Korea.
Yeonsook MoonDepartment of Laboratory Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, Republic of Korea.
Lucia KimDepartment of Pathology, Inha University Hospital, Inha University School of Medicine, Incheon, Republic of Korea.
Hae-Seong NamDivision of Pulmonology, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenCarcinoma, Non-Small-Cell LungInflammationLung NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorFemaleHumansMaleMiddle AgedPrognosisAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenBiomarkers, TumorCD274 protein, humanpembrolizumabbiomarkersnon-small-cell lung cancer (NSCLC)pembrolizumabprogrammed death-ligand 1 (PD-L1) expressionSystemic immune inflammation index (SII)

Identifiers

PMID42232607
PMCPMC13223186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.